Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2018-05-07 Capital/Financing Update
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Trading Halt Request 1 page 329.5KB
Capital/Financing Update Classification · 95% confidence The document is a formal letter requesting a trading halt from the ASX (Australian Securities Exchange) pursuant to ASX Listing Rule 17.1. The reason given is to allow the company to make an announcement regarding a proposed capital raising. The document does not contain financial data, results, or detailed report content but is an announcement related to capital market activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is clearly a request for a trading halt, not a report or announcement of results or voting.
2018-05-07 English
Appendix 4C - quarterly 5 pages 700.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated cash flow statements for the quarter ended 31 March 2018. It includes sections on cash flows from operating, investing, and financing activities, reconciliation of cash and cash equivalents, payments to directors and related parties, financing facilities, estimated cash outflows for the next quarter, and acquisitions/disposals. The document is approximately 8,799 characters long, which is substantial and contains actual financial data and analysis for a quarterly period. The presence of detailed financial statements and notes indicates this is a comprehensive interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2018-04-23 English
Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial 2 pages 465.8KB
Regulatory Filings Classification · 95% confidence The document is a brief update letter from Biotron Limited to the ASX regarding the progress of a Phase 2 clinical trial for their drug BIT225. It provides preliminary information about the trial status, safety, and assay development but does not contain any financial statements, detailed financial analysis, or comprehensive report data. The document is only 3693 characters long and is essentially an announcement or progress update rather than a full report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory certification or officer attestation. Given the nature and length, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements and updates that do not fit other specific categories.
2018-04-05 English
Half Yearly Report and Accounts 20 pages 323.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM FINANCIAL REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2017' and includes detailed financial statements such as the Directors' Report, Condensed Interim Statement of Profit or Loss, Statement of Financial Position, Cash Flows, Changes in Equity, Notes to the Financial Statements, Directors' Declaration, and Independent Auditor’s Review Report. It covers a half-year period ending 31 December 2017, which is a period shorter than a full fiscal year. The document contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2018-02-22 English
Appendix 4C - quarterly 5 pages 90.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed financial data including consolidated statements of cash flows for the current quarter and year to date, cash flow from operating, investing, and financing activities, estimated cash outflows for the next quarter, and compliance statements. The presence of actual financial figures and the quarterly period ending 31 December 2017 indicate this is a comprehensive quarterly financial report. The document is 8088 characters long, which is sufficient to contain substantive financial data rather than just an announcement or certification. The document aligns with the definition of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and contains substantive financial data and analysis. Therefore, the correct classification is IR (Interim / Quarterly Report).
2018-01-15 English
Biotron Presents to Biotech Showcase 2018 23 pages 1.6MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Biotron Limited at the Biotech Showcase 2018 conference. It includes extensive information about the company's antiviral drug platform, clinical trial progress, pipeline programs, key achievements, scientific validation, commercialisation strategy, corporate snapshot, board members, and investment highlights. The content is structured as a presentation with slides and detailed explanations, typical of investor presentations. There is no indication that this is an official annual or interim financial report, audit report, earnings release, or regulatory filing. The document is not a brief announcement or a voting result. It is a comprehensive presentation aimed at investors and stakeholders to inform them about the company's strategy, progress, and market position. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2018-01-09 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.